docetaxel-based chemotherapy. 140 In this study, the ORR was 22.8% and median PFS and OS were 3.8 and 6.2 months, respectively. The most common grade 3–4 toxicities were neutropenia (28.5%) and diarrhea (14.5%). The trifluridine and tipiracil regimen was
Search Results
Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology
Jaffer A. Ajani, Thomas A. D’Amico, David J. Bentrem, David Cooke, Carlos Corvera, Prajnan Das, Peter C. Enzinger, Thomas Enzler, Farhood Farjah, Hans Gerdes, Michael Gibson, Patrick Grierson, Wayne L. Hofstetter, David H. Ilson, Shadia Jalal, Rajesh N. Keswani, Sunnie Kim, Lawrence R. Kleinberg, Samuel Klempner, Jill Lacy, Frank Licciardi, Quan P. Ly, Kristina A. Matkowskyj, Michael McNamara, Aaron Miller, Sarbajit Mukherjee, Mary F. Mulcahy, Darryl Outlaw, Kyle A. Perry, Jose Pimiento, George A. Poultsides, Scott Reznik, Robert E. Roses, Vivian E. Strong, Stacey Su, Hanlin L. Wang, Georgia Wiesner, Christopher G. Willett, Danny Yakoub, Harry Yoon, Nicole R. McMillian, and Lenora A. Pluchino
Healthcare Utilization and End-of-Life Outcomes in Patients Receiving CAR T-Cell Therapy
P. Connor Johnson, Caron Jacobson, Alisha Yi, Anna Saucier, Tejaswini M. Dhawale, Ashley Nelson, Mitchell W. Lavoie, Mathew J. Reynolds, Carlisle E.W. Topping, Matthew J. Frigault, and Areej El-Jawahri
determine reasons for hospital readmissions. 12 In the schema for our study, these reasons included symptoms, fever without a source, febrile neutropenia, confirmed infection, dehydration/electrolyte abnormalities, planned hospitalization
Evaluation of Scores to Reflect Toxicity Impact on Quality of Life of Patients With Platinum-Resistant Ovarian Cancer: AURELIA Substudy
Justine Lequesne, Florence Joly, Julien Peron, Isabelle Ray-Coquard, Anne-Claire Hardy-Bessard, Frédéric Selle, Dominique Berton, Philippe Follana, Michel Fabbro, Alain Lortholary, Eric Pujade-Lauraine, Sophie Lefèvre-Arbogast, and Elodie Coquan
, respectively, whereas 113 (31.4%) experienced maximal-grade 2 AEs and 33 (9.2%) did not experience any grade ≥2 AEs. The most frequently observed AEs were fatigue (30.3%), neutropenia (28.6%), anemia (23.9%), abdominal pain (20%), and hypertension (15
First- and Second-Line Palliative Systemic Treatment Outcomes in a Real-World Metastatic Pancreatic Cancer Cohort
Esther N. Pijnappel, Willemieke P.M. Dijksterhuis, Lydia G. van der Geest, Judith de Vos-Geelen, Jan Willem B. de Groot, Marjolein Y.V. Homs, Geert-jan Creemers, Nadia Haj Mohammad, Marc G. Besselink, Hanneke W.M. van Laarhoven, Johanna W. Wilmink, and for the Dutch Pancreatic Cancer Group
of grade 3/4 toxicities (eg, neutropenia, thrombocytopenia, fatigue, vomiting). 13 , 27 , 28 Because the OS of patients receiving FOLFIRINOX in our study was higher among both those with PS 0–1 and those with PS 2 compared with those receiving
Frailty in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Receiving Curative-Intent Therapy: A Population-Based Study
Abi Vijenthira, Lee Mozessohn, Chenthila Nagamuthu, Ning Liu, Danielle Blunt, Shabbir Alibhai, Anca Prica, and Matthew C. Cheung
spent a significantly longer number of days in the hospital compared with nonfrail patients. During both time frames, the top 3 reasons for admission among both frail and nonfrail patients were fever/infection/neutropenia, lymphoma, and symptom
How to Choose Frontline Therapy for Chronic Myelogenous Leukemia: So Many Drugs, Not So Many Patients
Paul J. Shami
. Thrombocytopenia was more common with dasatinib, whereas neutropenia occurred at equal frequency. Edema, nausea, vomiting, and rashes were more common with imatinib. In earlier studies, pleural effusions were seen in patients treated with dasatinib, particularly at
Counterpoint: Adjuvant Therapy in Stage II Colon Cancer: Pain Not Justified by the Gain
Katherine Van Loon and Alan P. Venook
the MOSAIC trial, 0.5% of patients in each arm died during treatment and as many as 40% of patients experienced grade 3 or 4 neutropenia. 7 Moreover, although the addition of oxaliplatin possibly provides an absolute survival benefit of 1.5% compared
New Agents in Metastatic Prostate Cancer
Atish D. Choudhury and Philip W. Kantoff
was accompanied by increased toxicity compared with mitoxantrone, with higher rates of grade 3 or greater neutropenia (82% vs. 58%), neutropenic fever (8% vs. 1%), and diarrhea (6% vs. <1%), along with greater requirements for dose reductions (12% vs
Hematopoietic Progenitor Cell Transplantation in Children, Adolescents, and Young Adults With Relapsed Mature B-Cell NHL
Aliza Gardenswartz and Mitchell S. Cairo
-front in newly diagnosed DLBCL in combination with chemotherapy. 34 PV is generally well tolerated. The most common grade 3–4 events reported in the single-agent study by Palanca-Wessels et al 31 were neutropenia, anemia, and peripheral sensory neuropathy
Multiorgan Immune-Related Adverse Events During Treatment With Atezolizumab
Ganessan Kichenadasse, John O. Miners, Arduino A. Mangoni, Andrew Rowland, Ashley M. Hopkins, and Michael J. Sorich
not consider anemia (36 episodes), thrombocytopenia (7 episodes), neutropenia (5 episodes), and lymphopenia (3 episodes) to be irAEs. Table 2. Baseline Clinical Characteristics and Outcomes of Atezolizumab-Treated Patients Table 3. Baseline Laboratory
